• 1. Fe3O4/FeS2 heterostructures enable efficient oxygen evolution reaction?
  Xingqun Zheng,Lele Song,Xin Feng,Li Li,Zidong Wei J. Mater. Chem. A, 2020,8, 14145-14151
• 2. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 5. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837

Introduction to 1H-Imidazo[4,5-b]pyridin-2-amine, 6-bromo-1-methyl- (CAS No. 641617-45-0) and Its Emerging Applications in Chemical Biology and Medicinal Chemistry

The compound 1H-Imidazo[4,5-b]pyridin-2-amine, 6-bromo-1-methyl- (CAS No. 641617-45-0) represents a significant advancement in the field of chemical biology and medicinal chemistry. This heterocyclic molecule, characterized by its imidazopyridine core structure, has garnered considerable attention due to its versatile pharmacological properties and potential applications in drug discovery. The presence of a bromo substituent at the 6-position and a methyl group at the 1-position enhances its reactivity, making it a valuable scaffold for further chemical modifications and biological investigations.

Recent studies have highlighted the importance of imidazopyridine derivatives in the development of novel therapeutic agents. The 1H-Imidazo[4,5-b]pyridin-2-amine, 6-bromo-1-methyl- scaffold has been extensively explored for its ability to interact with various biological targets, including enzymes and receptors involved in critical cellular processes. Its unique structural features make it an attractive candidate for designing molecules with enhanced binding affinity and selectivity.

In the realm of medicinal chemistry, the bromo and methyl functional groups on this compound play a pivotal role in modulating its pharmacokinetic and pharmacodynamic properties. The bromo group, in particular, serves as a versatile handle for further derivatization via cross-coupling reactions, such as Suzuki-Miyaura or Buchwald-Hartwig couplings. These reactions allow for the introduction of diverse aryl or heteroaryl moieties, expanding the structural diversity of the resulting compounds. Such modifications are essential for optimizing drug-like properties, including solubility, bioavailability, and metabolic stability.

Moreover, the 1-methyl substituent contributes to the compound's overall stability and electronic properties, influencing its interaction with biological targets. The combination of these structural elements makes 1H-Imidazo[4,5-b]pyridin-2-amine, 6-bromo-1-methyl- a promising candidate for further exploration in the design of small-molecule inhibitors and activators.

One of the most compelling aspects of this compound is its potential application in addressing unmet medical needs. Emerging research suggests that imidazopyridine derivatives exhibit inhibitory activity against various enzymes implicated in inflammatory diseases, cancer, and infectious disorders. For instance, studies have demonstrated that compounds structurally related to 1H-Imidazo[4,5-b]pyridin-2-amine, 6-bromo-1-methyl- can modulate the activity of Janus kinases (JAKs), which are key mediators of inflammatory responses. By targeting these enzymes, such molecules hold promise for developing novel anti-inflammatory therapies with improved efficacy and reduced side effects compared to existing treatments.

Additionally, the bromo substituent on this compound has been leveraged in the development of kinase inhibitors. Kinases are critical enzymes involved in cell signaling pathways that regulate processes such as cell growth, differentiation, and survival. Inhibiting aberrant kinase activity is a major strategy in oncology research. Preclinical studies have shown that imidazopyridine-based inhibitors can effectively disrupt oncogenic signaling pathways by binding to specific kinase domains. The methyl group at position 1 further fine-tunes the binding interactions, enhancing selectivity against target kinases while minimizing off-target effects.

The versatility of 1H-Imidazo[4,5-b]pyridin-2-amine, 6-bromo-1-methyl-* also extends to its potential use as a tool compound in chemical biology research. Researchers have utilized this scaffold to develop probes that can interact with specific biological targets in vitro and in vivo. These probes provide valuable insights into cellular mechanisms and can aid in identifying novel therapeutic targets. For example, fluorescently labeled derivatives of this compound have been employed to visualize kinase activity in living cells, enabling real-time monitoring of signaling events.

In conclusion,1H-imidazo[4,5-b]pyridin²-amine, 6-bromo^-1-methyl-(CAS No.641617-45-0) stands out as a versatile and promising scaffold with significant implications for drug discovery and chemical biology.Thebromoandmethylsubstituentsenhanceitsreactivityandbindingaffinity,Making it an ideal candidate for designing novel therapeutic agents targeting various diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)